These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that Xinjiang...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board...
More--2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms -- --1H19 Total Sales Up...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
More--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING, May 10, 2019...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
More-- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its...
MoreChina Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...
More3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Directors Approves...
More